The effect of aging on circulating levels of proinflammatory cytokines during septic shock

Journal of the American Geriatrics Society

Volumn 49, Issue 1, 2001, Pages 5-9

  Marik, Paul E ^a   Zaloga, Gary P ^b  

^a MERCY HOSPITAL OF PITTSBURGH   (United States)

^b SUBURBAN HOSPITAL   (United States)

Author keywords

Age; Cytokines; Gender; Interleukin 1; Interleukin 6; Older; Septic shock; Soluble tumor necrosis factor receptors; Tumor necrosis factor

Indexed keywords

CYTOKINE; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ADULT; AGED; AGING; ARTICLE; CANADA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; INTENSIVE CARE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; SEPSIS; SEPTIC SHOCK; SEX DIFFERENCE; SURVIVAL; UNITED STATES;

AGED; AGED, 80 AND OVER; AGING; ANTIBODIES, MONOCLONAL; COHORT STUDIES; CYTOKINES; DOUBLE-BLIND METHOD; HUMANS; INTERLEUKIN-1; MIDDLE AGED; RECEPTORS, TUMOR NECROSIS FACTOR; SHOCK, SEPTIC; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0035120112     PISSN: 00028614     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1532-5415.2001.49003.x     Document Type: Article

References (65)

1. Epidemiology, pathophysiology and clinical presentation of gram-negative sepsis
2. Trends in infectious disease hospitalizations in the United States, 1980-1994
3. Interleukin 1 induces a shock like state in rabbits: Synergism with tumor necrosis factor and the effect of cyclooxygenase inhibition
4. Role of cytokines in sepsis
5. Antibodies to cachectin/tumor necrosis factor reduce interleukin 1 beta and interleukin 6 appearance during lethal bacteremia
6. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteremia
7. Shock and tissue injury induced by recombinant human cachectin
8. Tumor necrosis factor alpha and interleukin 1beta are responsible for in vitro myocardial cell depression induced by human septic shock serum
9. Adjunctive therapy for septic shock: A review of experimental approaches
10. Experimental therapies for sepsis directed against tumor necrosis factor
11. Issues in the adjunctive therapy of severe sepsis
12. New therapies in sepsis
13. Anti-inflammatory therapies to treat sepsis and septic shock: A reassessment
14. Lower serum concentrations of cytokines in elderly patients with pneumonia and the impaired production of cytokines by peripheral blood monocytes in the elderly
15. Cytokine production pathway in the elderly
16. Influence of age on the production and regulation of interleukin-1 in mice
17. Evidence for lowered induction of nuclear factor kappa B in activated human T lymphocytes during aging
18. Nuclear factor-κB: A pivotal transcription factor in chronic inflammatory diseases
19. Quantitative intracellular cytokine measurement: Age-related changes in proinflammatory cytokine production
20. Interleukin-6 and selected plasma proteins in healthy persons of different ages
21. Serum IL-6 level and the development of disability in older persons
22. Afebrile bacteremia. A phenomenon in geriatric patients
23. Age-related differences in the metabolic response to injury
24. Mortality in elderly patients with thermoregulatory failure
25. Double-blind randomized controlled trial of monoclonal antibody to human tumor necrosis factor in treatment of septic shock
26. The pathophysiologic roles of interleukin-6 in human disease
27. Proinflammatory and anti-inflammatory cytokines as mediators in the pathogenesis of septic shock
28. Interleukin-6 (IL-6) as an anti-inflammatory cytokine: Induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55
29. T cell activation-associated hepatic injury: Mediation by tumor necrosis factors and protection by interleukin 6
30. The role of IL-4 and IL-6 in IL-1-dependent cartilage matrix degradation
31. Characterization in vitro of a human tumor necrosis factor-binding protein: A soluble form of a tumor necrosis factor receptor
32. Protection against a lethal dose of endotoxin by an inhibitor of tumor necrosis factor processing
33. Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor alpha in vitro and in vivo
34. Decline in the production of interleukin-3 with age in mice
35. Monokine secretion in aging and protein malnutrition
36. The cell biology of aging: Immunological models
37. Immunodeficiency of the elderly
38. The cellular and subcellular bases of immunosenescence
39. Immunologic studies of aging. V. Impaired proliferation of PHA responsive human lymphocytes in culture
40. Decreased proliferation, interleukin 2 synthesis, and interleukin 2 receptor expression are accompanied by decreased M RNA expression in phyto-hemagglutinin-stimulated cells from elderly donors
41. Effect of age on the human high affinity interleukin 2 receptor of phytohemagglutinin stimulated peripheral blood lymphocytes
42. Dysregulation between TH1 and TH2 T cell subpopulations in the elderly
43. The pituitary-adrenal glucocorticoid response is altered by gender and disease
44. Relation of age to left ventricular function in clinically normal adults
45. Heart failure associated with preserved systolic function: A common and costly clinical entity
46. Time course of cytokine levels in sepsis
47. Cytokine appearance in human endoroxemia and primate bacteremia
48. Cachectin/tumor necrosis factor: Production, distribution, and metabolic fate in vivo
49. A primer on cytokines: Sources, receptors, effects, and inducers
50. Infusion of tumor necrosis factor (TNF) causes an increase in circulating TNF-binding protein in humans
51. Soluble tumor necrosis factor receptors in febrile neutropenic cancer patients
52. Tumor necrosis factor (TNF)-dependent shedding of the p55 TNF receptor in a baboon model of bacteremia
53. Elderly humans show prolonged in vivo inflammatory activity during pneumococcal infections
54. Release of interleukin-12 in experimental Escherichia coli septic shock in baboons: Relation to plasma levels of interleukin-10 and interferon-gamma
55. Serum cytokine levels in human septic shock: Relation to multiple-system organ failure and mortality
56. Interleukin-10: Biology, role in inflammation and autoimmunity
57. Interleukin-10 is a central regulator of the response to LPS in murine models of endotoxic shock and the Shwartzman reaction but not endotoxin tolerance
58. Interleukin-10 protects mice from lethal endotoxemia
59. Anti-inflammatory cytokine profile and mortality in febrile patients
60. Hypothesis: Compartmentalization of cytokines in intraabdominal infection
61. Inflammatory response in peritoneal exudate and plasma of patients undergoing planned relaparotomy for severe secondary peritonitis
62. Effect of mechanical ventilation on inflammatory mediators in patients with acute respiratory distress syndrome: A randomized controlled trial
63. Inflammatory mediators in bronchoalveolar lavage fluid and plasma in leukocytopenic patients with septic shock-induced acute respiratory distress syndrome
64. Cytokines and soluble cytokine receptors in pleural effusions from septic and nonseptic patients